Jonathan Webster
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Johns Hopkins University · Eisai Limited
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan Webster as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:02 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06803745 · Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Acute Leukemia, Acute Lymphoblastic Lymphoma · principal investigator
- Ph1NCT05506956 · Post-transplant Flotetuzumab for AMLSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Leukemia, Myeloid, Acute · principal investigator
- Ph1/Ph2NCT03114865 · A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenanceSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia · principal investigator
- Ph2NCT01172379 · A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period DyskinesiasEisai Limited · completed · Parkinson's Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bispecific Antibody Maintenance Therapy after Allogeneic Bone Marrow TransplantK08CA276987 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2023 to 2026 · $237,049 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Bone Marrow Transplantation in Human DiseaseP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI RICHARD J JONES · fiscal years 1985 to 2016Named on NCT05506956
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:02 UTC. The ranking covers the 200 most relevant of 212 PubMed records, and a shared surname and initials can bring in a namesake. All 212 on PubMed
- 1,230 citationsRCR 36.6
- Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.Nat Genet · 20071,127 citationsRCR 23.3
- 1,049 citationsRCR 29.8
- The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.Arch Intern Med · 2002647 citationsRCR 15.7
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.Nat Med · 2019557 citationsRCR 18.3
- A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.N Engl J Med · 1994494 citationsRCR 18.2
- 383 citationsRCR 11.3
- Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.Lancet · 1983334 citationsRCR 15.5
- 282 citationsRCR 13.8
- 267 citationsRCR 15.1